Discontinuation of first-line DMTs among patients with stable MS for at least 5 years may lead to an increased risk for recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback